MABRON INJECTION

Kraj: Malezja

Język: angielski

Źródło: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Kup teraz

Ulotka dla pacjenta Ulotka dla pacjenta (PIL)
19-07-2021

Składnik aktywny:

TRAMADOL HYDROCHLORIDE

Dostępny od:

KOMEDIC SDN BHD

INN (International Nazwa):

TRAMADOL HYDROCHLORIDE

Sztuk w opakowaniu:

2.0ml mL

Wyprodukowano przez:

MEDOCHEMIE LTD (AMPOULE INJECTABLE FACILITY)

Ulotka dla pacjenta

                                Not Applicable
                                
                                Przeczytaj cały dokument
                                
                            

Charakterystyka produktu

                                MABRON
COMPOSITION
2ml of aqueous solution for injection contain 100mg of Tramadol HCl.
This is equivalent to one ampoule MABRON. The chemical
designation is
(+)-trans-2-(dimethlaminomethyl)-1-(m-methoxyphenyl)-cyclohexanol-hydrochloride.
PRESENTATION
A solution for injection or infusion containing 50mg of tramadol
hydrochloride per 1ml was developed. The solution is
presented as a clear, colorless or almost colorless solution in Type I
(Ph.Eur) amber glass ampoules, of nominal volume 2.0ml.
INDICATIONS
Treatment of moderate to severe pain.
PHARMACOLOGY
_PHARMACODYNAMIC PROPERTIES _
Pharmacotherapeutic group: other opioids; ATC-code N 02: AX 02.
Tramadol is a centrally acting opioid analgesic. It is a non-selective
pure agonist at μ, δ and κ opioid receptors with a higher
affinity for the μ receptor. Other mechanisms which contribute to its
analgesic effect are inhibition of neuronal reuptake of
noradrenaline and enhancement of serotonin release.
Tramadol has an antitussive effect. In contrast to morphine, analgesic
doses of tramadol over a wide range have no respiratory
depressant effect. Also gastrointestinal motility is less affected.
Effects on the cardiovascular system tend to be slight. The
potency of tramadol is reported to be 1/10 (one tenth) to 1/6 (one
sixth) that of morphine.
_PHARMACOKINETIC PROPERTIES _
More than 90% of tramadol is absorbed after oral administration. The
mean absolute bioavailability is approximately 70%,
irrespective of the concomitant intake of food. The difference between
absorbed and non-metabolised available tramadol is
probably due to the low first-pass effect. The first-pass effect after
oral administration is a maximum of 30 %.
Tramadol has a high tissue affinity (V
d,ß
= 203 ± 40 l). It has a plasma protein binding of about 20%.
Following a single oral dose administration of tramadol 100mg as
capsules or tablets to young healthy volunteers, plasma
concentrations were detectable within approximately 15 to 45 minutes
within a mean C
max
of 280 to 208 mcg/L and T
max
of 1
                                
                                Przeczytaj cały dokument
                                
                            

Wyszukaj powiadomienia związane z tym produktem

Zobacz historię dokumentów